ClinicalTrials.gg
CompletedNCT02446899Updated Jan 10, 2023Results posted

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

A Phase 3 interventional study of Anifrolumab and Placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 113 sites in 15 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
5th of 20
373 · median 159
Started
2015
with 1 other
Phase 3
9 of 20
4 open now
Registered
4th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 5th largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 4th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Read the detailed description

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. The study will be performed in adult participants aged 18 to 70 years of age.

Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed intravenous dose of anifrolumab 300 mg or placebo every 4 weeks for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous infusion (IV) via an infusion pump over a minimum of 30 minutes, every 4 weeks.

03

Conditions studied

  • Active Systemic Lupus Erythematosus

Keywords

  • Active Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 through 70 years at the time of screening
  2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982 revised criteria ≥24 weeks prior to signing the form (ICF)
  3. Currently receiving at least 1 of the following:

    1. Where prednisone is the single standard of care medication (ie, the subject is not concurrently receiving any medication listed in inclusion criterion 3(c)), a dose of oral prednisone ≥7.5 mg/day but ≤40 mg/day (or prednisone equivalent) for a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation
    2. Where prednisone is not the single standard of care medication (ie, the subject is concurrently receiving at least one medication listed in inclusion criterion 3(c), a dose of oral prednisone (≤40 mg/day) (or prednisone equivalent) for a minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.
    3. Any of the following medications administered for a minimum of 12 weeks prior to signing the informed consent, and at a stable dose for a minimum of 8 weeks prior to signing the informed consent and through Day 1:

    (i) Azathioprine ≤200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day

  4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:

    1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay (IFA) at the central laboratory with titre ≥1:80; OR
    2. Anti-dsDNA antibodies at screening elevated to above normal (including indeterminate), as per the central laboratory; OR
    3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the central laboratory
  5. At Screening, Disease Activity Adjudication Group confirmation of:

    SLEDAI-2K Criteria: SLEDAI-2K score ≥6 points and "Clinical" SLEDAI-2K score ≥4 points. The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures.

  6. Must not have active or latent TB on either chest radiograph or by quantiferon gold test
  7. Day 1 "Clinical" SLEDAI-2K score ≥4 points
  8. OCS dose stable for at least 2 weeks prior to randomisation
  9. Stable SLE SOC treatment at the time of randomisation
  10. Women of must have a negative serum β-hCG test at and negative urine pregnancy test at randomisation prior to administration of product

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater
  2. Receipt of any of the following:

    (a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1

  3. History of, or current diagnosis of, a non SLE-related vasculitis syndrome.
  4. Active severe or unstable neuropsychiatric SLE
  5. Active severe SLE-driven renal disease
  6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE or SSc.
  7. History of, or current, inflammatory joint or skin disease other than SLE
  8. History of any non-SLE disease that has required treatment with oral or parenteral for more than 2 weeks within the last 24 weeks prior to signing the ICF
  9. 26.27. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation
  10. Confirmed positive test for or
  11. Any severe herpes infection at any time prior to Week 0 (Day 1)
  12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial treatment within 3 years prior to randomization
  13. History of cancer, apart from:

    1. Squamous or basal cell carcinoma of the skin that has been successfully treated
    2. Cervical cancer in situ that has been successfully treated
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.

    Biological: Anifrolumab

  • Placebo comparator
    Placebo

    Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.

    Drug: Placebo

Interventions

  • BiologicalAnifrolumab

    Intravenous infusion (IV)

  • DrugPlacebo

    Intravenous infusion (IV)

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52

    Composite endpoint BICLA was defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

    Time frame: Baseline; Week 52

Secondary outcomes

  1. Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group

    Defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

    Time frame: Baseline; Week 52

  2. Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day

    Maintained OCS reduction was defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

    Time frame: Week 40; Week 52

  3. Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10

    50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

    Time frame: Baseline; Week 12

  4. Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline

    50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction from baseline in the number of swollen and tender joints, separately * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

    Time frame: Baseline; Week 52

  5. Annualised Flare Rate Through 52 Weeks

    A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.

    Time frame: Baseline to Week 52

  6. Number of Participants With One or More Adverse Events (AEs)

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.

    Time frame: Baseline to end of study (Maximum of 60 weeks)

  7. Number of Participants With One or More Adverse Events of Special Interest (AESIs)

    An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus \[SLE\]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction \[MI\], or cardiovascular death). AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to end of study (Maximum of 60 weeks)

  8. Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements

    Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate. Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to end of study (Maximum of 60 weeks)

  9. Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests

    Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

    Time frame: Baseline to end of study (Maximum of 60 weeks)

07

Results

Posted Mar 18, 2020

Participant flow

Participants took part in the trial at 119 sites in 15 countries worldwide.

Participant flow — Overall Study
MilestoneAnifrolumab 300 mgPlacebo
Started181184
Received study drug180182
Completed156136
Not completed2548
Withdrew: Adverse event47
Withdrew: Condition under investigation worsened14
Withdrew: Study specific withdrawal criteria10
Withdrew: Lack of efficacy28
Withdrew: Lost to follow-up13
Withdrew: Severe non-compliance to protocol01
Withdrew: Withdrawal by subject1119
Withdrew: Miscellaneous54
Withdrew: Failure to meet randomization criteria02

Outcome measures

PrimaryNumber of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52

Composite endpoint BICLA was defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

Time frame:
Baseline; Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 528657
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0013 (Nominal p-value.) · Mean difference (final values): 16.3 · 95% CI 6.3 to 26.3
SecondaryNumber of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group

Defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

Time frame:
Baseline; Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group7246
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0022 (Adjusted p-value.) · Mean difference (final values): 17.3 · 95% CI 6.5 to 28.2
SecondaryNumber of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day

Maintained OCS reduction was defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

Time frame:
Week 40; Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day4525
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0135 (Adjusted p-value.) · Mean difference (final values): 21.2 · 95% CI 6.8 to 35.7
SecondaryNumber of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10

50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

Time frame:
Baseline; Week 12
Reported as:
Count of participants · Participants
Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥102410
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0392 (Adjusted p-value.) · Mean difference (final values): 24.0 · 95% CI 4.3 to 43.6
SecondaryNumber of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline

50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction from baseline in the number of swollen and tender joints, separately * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

Time frame:
Baseline; Week 52
Reported as:
Count of participants · Participants
Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline3034
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5469 (Adjusted p-value) · Mean difference (final values): 4.7 · 95% CI -10.6 to 20.0
SecondaryAnnualised Flare Rate Through 52 Weeks

A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.

Time frame:
Baseline to Week 52
Reported as:
Number · Annualized flare rate ratio
Annualised Flare Rate Through 52 Weeks
Annualized flare rate ratioAnifrolumab 300 mgPlacebo
Annualised Flare Rate Through 52 Weeks0.43 (0.31 to 0.59)0.64 (0.47 to 0.86)
Statistical analysis
  • Anifrolumab 300 mg vs Placebo · Negative binomial regression · p = 0.0809 (Adjusted p-value.) · Rate ratio: 0.67 · 95% CI 0.48 to 0.94
SecondaryNumber of Participants With One or More Adverse Events (AEs)

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.

Time frame:
Baseline to end of study (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs)
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants With One or More Adverse Events (AEs)162154
SecondaryNumber of Participants With One or More Adverse Events of Special Interest (AESIs)

An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus \[SLE\]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction \[MI\], or cardiovascular death). AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to end of study (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events of Special Interest (AESIs)
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants With One or More Adverse Events of Special Interest (AESIs)2920
SecondaryNumber of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements

Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate. Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to end of study (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements4545
SecondaryNumber of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests

Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).

Time frame:
Baseline to end of study (Maximum of 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests
ParticipantsAnifrolumab 300 mgPlacebo
Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests7287

Adverse events

Collected over Day 1 to end of study (Maximum of 60 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab 300 mg1/180 (0.6%)16/180 (8.9%)125/180 (69.4%)
Placebo0/182 (0%)34/182 (18.7%)99/182 (54.4%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventAnifrolumab 300 mgPlacebo
PneumoniaInfections and infestations3/1807/182
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/1806/182
Gastroenteritis viralInfections and infestations2/1800/182
Radius fractureInjury, poisoning and procedural complications0/1802/182
Acute coronary syndromeCardiac disorders1/1800/182
Chilaiditi's syndromeGastrointestinal disorders1/1800/182
HypersensitivityImmune system disorders1/1800/182
AppendicitisInfections and infestations1/1800/182
DiverticulitisInfections and infestations1/1800/182
Herpes zosterInfections and infestations1/1800/182
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAnifrolumab 300 mgPlacebo
Upper respiratory tract infectionInfections and infestations42/18019/182
NasopharyngitisInfections and infestations28/18023/182
Urinary tract infectionInfections and infestations21/18026/182
Infusion related reactionInjury, poisoning and procedural complications25/18014/182
BronchitisInfections and infestations23/1808/182
HeadacheNervous system disorders11/18018/182
SinusitisInfections and infestations13/1809/182
Herpes zosterInfections and infestations12/1803/182
Back painMusculoskeletal and connective tissue disorders11/1803/182
ArthralgiaMusculoskeletal and connective tissue disorders10/1806/182

Baseline characteristics

Full analysis set: All participants who were randomized and received at least one dose of the study drug. 3 participants discontinued the study prior to receiving the study drug and are not included in the full analysis set.

Age, Categorical
Age, Categorical(Participants)Anifrolumab 300 mgPlaceboTotal
<=18 years000
Between 18 and 65 years175181356
>=65 years516
Age, Continuous
Age, Continuous(Years)Anifrolumab 300 mgPlaceboTotal
Mean43.1 ± 11.9541.1 ± 11.4742.1 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)Anifrolumab 300 mgPlaceboTotal
Female168170338
Male121224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anifrolumab 300 mgPlaceboTotal
Hispanic or Latino5454108
Not Hispanic or Latino118120238
Unknown or Not Reported8816
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Anifrolumab 300 mgPlaceboTotal
White110107217
Black or African American172542
Asian303060
Native Hawaiian or Other Pacific Islander000
American Indian or Alaska Native415
Other111122
Missing8816
Geographic region
Geographic region(Participants)Anifrolumab 300 mgPlaceboTotal
Asia Pacific272653
Europe514697
Latin America353267
United States/Canada6468132
Rest of World (South Africa)31013
08

Study locations

113 sites
  • Research Site
    Covina, California 91723, United States
  • Research Site
    Hemet, California 92543-4403, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Leandro, California 94578, United States
  • Research Site
    Torrance, California 90509, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Bridgeport, Connecticut 06606, United States
  • Research Site
    Bridgeport, Connecticut 6606, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Tamarac, Florida 33321, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Atlanta, Georgia 30303, United States
  • Research Site
    Boston, Massachusetts 02118, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Lincoln, Nebraska 68516, United States
  • Research Site
    Las Cruces, New Mexico 88011, United States
  • Research Site
    Brooklyn, New York 11201, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Memphis, Tennessee 38163, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77034, United States
  • Research Site
    Stafford, Texas 77477, United States
  • Research Site
    Arlington, Virginia 22205, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Buenos Aires, C1015ABO, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Quilmes, 1878, Argentina
  • Research Site
    Bruxelles, 1070, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liege, B-4000, Belgium
  • Research Site
    Merksem, B-2170, Belgium
  • Research Site
    Goiania, 74110-120, Brazil
  • Research Site
    Juiz de Fora, 36010 570, Brazil
  • Research Site
    Sao Paulo, 04032-060, Brazil
  • Research Site
    Sao Paulo, 05403-9000, Brazil
  • Research Site
    Sao Paulo, 05652-900, Brazil
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Hamilton, Ontario L8S 4K1, Canada
  • Research Site
    Rimouski, Quebec G5L 5T1, Canada
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Montpellier CEDEX 5, 34295, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Paris, 75679, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Toulouse, 31000, France
  • Research Site
    Berlin, D-10117, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    München, 80336, Germany
  • Research Site
    Chiba-shi, 260-8712, Japan
  • Research Site
    Chuo-ku, 104-8560, Japan
  • Research Site
    Fukuoka-shi, 810-8539, Japan
  • Research Site
    Fukuoka-shi, 810-8563, Japan
  • Research Site
    Hiroshima-shi, 730-8619, Japan
  • Research Site
    Kitakyushu-shi, 807-8555, Japan
  • Research Site
    Kurashiki-shi, 710-8522, Japan
  • Research Site
    Meguro-ku, 152-8902, Japan
  • Research Site
    Meguro-ku, 153-8515, Japan
  • Research Site
    Nagasaki-shi, 852-8501, Japan
  • Research Site
    Nagoya-shi, 460-0001, Japan
  • Research Site
    Omura-shi, 856-8562, Japan
  • Research Site
    Sapporo-shi, 060-8638, Japan
  • Research Site
    Sasebo-shi, 857-1195, Japan
  • Research Site
    Sendai-shi, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Tsukuba, 305-8577, Japan
  • Research Site
    Jeju-si, 690-767, Korea, Republic of
  • Research Site
    Seoul, 05030, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 133792, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Kaunas, LT-50009, Lithuania
  • Research Site
    Klaipeda, LT-92288, Lithuania
  • Research Site
    Chihuahua, 31000, Mexico
  • Research Site
    Leon, 37000, Mexico
  • Research Site
    Mexico D.F., 014080, Mexico
  • Research Site
    Mexico, 06700, Mexico
  • Research Site
    Morelia, 58070, Mexico
  • Research Site
    Mérida, 97000, Mexico
  • Research Site
    San Luis Potosí, 78213, Mexico
  • Research Site
    Kemerovo, 650066, Russian Federation
  • Research Site
    Petrozavodsk, 185019, Russian Federation
  • Research Site
    Smolensk, 214015, Russian Federation
  • Research Site
    Tolyatti, 445039, Russian Federation
  • Research Site
    Vladimir, 600023, Russian Federation
  • Research Site
    Yaroslavl, 150003, Russian Federation

Showing the first 100 of 113 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bruce IN, van Vollenhoven RF, Morand EF, Furie RA, Manzi S, White WB, Abreu G, Tummala R. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). 2023 Apr 3;62(4):1526-1534. doi: 10.1093/rheumatology/keac491. PubMed 36018235 ↗
  • Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 Jul;81(7):962-969. doi: 10.1136/annrheumdis-2021-221847. Epub 2022 May 17. PubMed 35580976 ↗
  • Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. PubMed 35338035 ↗
  • Loncharich MF, Anderson CW. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14. PubMed 35157371 ↗
  • Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022 May 5;61(5):1900-1910. doi: 10.1093/rheumatology/keab704. PubMed 34528084 ↗
  • Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul;30(8):1254-1263. doi: 10.1177/09612033211014267. Epub 2021 May 12. PubMed 33977796 ↗
  • Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, Pineda L, Tummala R. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Arthritis Rheumatol. 2021 Nov;73(11):2059-2068. doi: 10.1002/art.41778. Epub 2021 Sep 22. PubMed 33913260 ↗
  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗
  • Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. PubMed 31851795 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Sep 2018, 38 months.

Results were first posted in Mar 2020, 1 year 5 months after primary completion. A results delay was requested in Aug 2019.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 18, 2015
StartActual
Jul 9, 2015
Primary completionActual
Sep 27, 2018
CompletionActual
Sep 27, 2018
Results delay requested
Aug 13, 2019
Results first posted
Mar 18, 2020
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02446899
Lead sponsor
AstraZeneca
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Jul 9, 2015
Primary completion
Sep 27, 2018
Completion
Sep 27, 2018
Results posted
Mar 18, 2020
Last update
Jan 10, 2023

Study contacts

Lilia Pineda, MD
study director · Medical Science Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion